Seminars in Oncology
Volume 36 , Pages S52-S58 , April 2009

Role of c-Met in Cancer: Emphasis on Lung Cancer

  • Ravi Salgia

      Affiliations

    • Corresponding Author InformationAddress correspondence to Ravi Salgia, MD, PhD, Department of Medicine, University of Chicago, Pritzker School of Medicine, 5841 S Maryland Ave, Chicago, IL 60637

References 

  1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915–925
  2. Zhang YW, Vande Woude GF. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem. 2003;88:408–417
  3. Rosario M, Birchmeier W. How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol. 2003;13:328–335
  4. Zillhardt M, Sawada K, Jagadeeswaran S, Temkin S, Yamada D, Buller R, et al. The c-Met/VEGFR2 inhibitor, XL880, inhibits ovarian cancer cell growth [abstract]. AACR Meeting Abstracts. 2008;4839.
  5. Bardelli A, Ponzetto C, Comoglio PM. Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering. J Biotechnol. 1994;37:109–122
  6. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005;225:1–26
  7. Hepatocyte growth factor/scatter factor, Met and cancer references. http://www.vai.org/met/Accessed December 22, 2008
  8. Graveel C, Su Y, Koeman J, Wang LM, Tessarollo L, Fiscella M, et al. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci U S A. 2004;101:17198–17203
  9. Cheng TL, Chang MY, Huang SY, Sheu CC, Kao EL, Cheng YJ, et al. Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer. Chest. 2005;128:1453–1460
  10. Jagadeeswaran R, Jagadeeswaran S, Bindokas VP, Salgia R. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol. 2007;292:L1488–L1494
  11. Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res. 2002;8:620–627
  12. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003;22:309–325
  13. Maulik G, Madhiwala P, Brooks S, Ma PC, Kijima T, Tibaldi EV, et al. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J Cell Mol Med. 2002;6:539–553
  14. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005;65:1479–1488
  15. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 2007;67:1670–1679
  16. Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu MY, et al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology. 2008;Epub ahead of print
  17. Kong DS, Song SY, Kim DH, Joo KM, Yoo JS, Koh JS, et al. Prognostic significance of c-Met expression in glioblastomas. Cancer. 2009;115:140–148
  18. Drebber U, Baldus SE, Nolden B, Grass G, Bollschweiler E, Dienes HP, et al. The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep. 2008;19:1477–1483
  19. Yu L, Saile K, Swartz CD, He H, Zheng X, Kissling GE, et al. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas. Mol Med. 2008;14:264–275
  20. Matsushita A, Gotze T, Korc M. Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1. Cancer Res. 2007;67:10309–10316
  21. Timpson P, Wilson AS, Lehrbach GM, Sutherland RL, Musgrove EA, Daly RJ. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res. 2007;67:9304–9314
  22. Garcia S, Dales JP, Charafe-Jauffret E, Carpentier-Meunier S, ndrac-Meyer L, Jacquemier J, et al. Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis. Int J Oncol. 2007;31:49–58
  23. Garcia S, Dales JP, Jacquemier J, Charafe-Jauffret E, Birnbaum D, ndrac-Meyer L, et al. c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. Br J Cancer. 2007;96:329–335
  24. Natali PG, Prat M, Nicotra MR, Bigotti A, Olivero M, Comoglio PM, et al. Overexpression of the met/HGF receptor in renal cell carcinomas. Int J Cancer. 1996;69:212–217
  25. Fischer J, Palmedo G, von Knobloch R, Bugert P, Prayer-Galetti T, Pagano F, et al. Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours. Oncogene. 1998;17:733–739
  26. Tsao MS, Liu N, Chen JR, Pappas J, Ho J, To C, et al. Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer. 1998;20:1–16
  27. Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene. 2003;22:4150–4165
  28. Gou S, Liu T, Wang C, Yin T, Li K, Yang M, et al. Establishment of clonal colony-forming assay for propagation of pancreatic cancer cells with stem cell properties. Pancreas. 2007;34:429–435
  29. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell. 2005;121:823–835
  30. Chen JT, Lin TS, Chow KC, Huang HH, Chiou SH, Chiang SF, et al. Cigarette smoking induces overexpression of hepatocyte growth factor in type II pneumocytes and lung cancer cells. Am J Respir Cell Mol Biol. 2006;34:264–273
  31. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. 2002;13:41–59
  32. Salgia R, Li JL, Lo SH, Brunkhorst B, Kansas GS, Sobhany ES, et al. Molecular cloning f human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. J Biol Chem. 1995;270:5039–5047
  33. Playford MP, Schaller MD. The interplay between Src and integrins in normal and tumor biology. Oncogene. 2004;23:7928–7946
  34. Mattiussi S, Matsumoto K, Illi B, Martelli F, Capogrossi MC, Gaetano C. Papilloma protein E6 abrogates shear stress-dependent survival in human endothelial cells: evidence for specialized functions of paxillin. Cardiovasc Res. 2006;70:578–588
  35. Salgia R, Li JL, Ewaniuk DS, Wang YB, Sattler M, Chen WC, et al. Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene. 1999;18:67–77
  36. Pasternak G, Hochhaus A, Schultheis B, Hehlmann R. Chronic myelogenous leukemia: molecular and cellular aspects. J Cancer Res Clin Oncol. 1998;124:643–660
  37. Dharmawardana PG, Giubellino A, Bottaro DP. Hereditary papillary renal carcinoma type I. Curr Mol Med. 2004;4:855–868
  38. Salvi A, Marchina E, Benetti A, Grigolato P, De Petro G, Barlati S. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients. Int J Oncol. 2008;33:271–276
  39. Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, Mackinnon AC, Seiwert TY, et al. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res. 2008;68:132–142
  40. Siddiqui SS, Loganathan S, Krishnaswamy S, Faoro L, Jagadeeswaran R, Salgia RC. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C (elegans vulva phenotypes). Cancer Biol Ther. 2008;7:856-3
  41. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452:638–642
  42. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452:633–637
  43. Reardon DA, Cloughsey TF, Raizer JJ, Laterra J, Schiff D, Tang X, et al. Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme [abstract]. J Clin Oncol. 2008;26:2051
  44. Zillhardt M, Sawada K, Jagadeeswaran S, Temkin S, Yamada D, Buller R, et al. The c-Met/VEGFR2 inhibitor, XL880, inhibits ovarian cancer cell growth [abstract]. AACR Meeting Abstracts. 2008;4839
  45. Clinical trials with AMG-102 as single agent or in combination in solid tumors. http://www.clinicaltrials.gov/Accessed December 29, 2008
  46. Clinical trials with small molecule inhibitors of c-Met (HGFR). http://www.clinicaltrials.gov/Accessed December 29, 2008
  47. Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer. 2007;97:368–377
  48. Jagadeeswaran R, Puri N, Ma PC, Jagadeesh S, Schaefer E, Christensen J, et al. c-Met/HGF pathway and the role of reactive oxygen species in small cell lung cancer cells [abstract 429]. AACR Meeting Abstracts. 2004;42c.
  49. Puri N, Ahmed S, Janamanchi V, Treitokova M, Krausz T, Jagadeeswaran R, et al. c-Met is a new therapeutic target for treatment of human melanoma [abstract]. AACR Meeting Abstracts. 2005;1406.
  50. Puri N, Salgia R. Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog. 2008;7:9
  51. Salgia R. c-Met receptor tyrosine kinase as a therapeutic target in cancer. American Society of Clinical Oncology Educational Book. 2008;113–118
  52. Sattler M, Pisick E, Morrison PT, Salgia R. Role of the cytoskeletal protein paxillin in oncogenesis. Crit Rev Oncol. 2000;11:63–76

 STATEMENT OF CONFLICT OF INTEREST: Dr Salgia reports serving on the Scientific Advisory Board for Cephalon and Biogen Idec, and as a Consultant for Merck.

 This work in part is supported by the NIH/NCI (2R01CA100750-05A1, 5R01CA125541-03, 1R01CA129501-01A1, 2P01HL058064-13), MARF (Jefferey P. Hayes Memorial), Cancer Research Foundation (Goldblatt Award) and V-Foundation (Guy Geelerd Memorial Foundation).

PII: S0093-7754(09)00036-0

doi: 10.1053/j.seminoncol.2009.02.008

Seminars in Oncology
Volume 36 , Pages S52-S58 , April 2009

Article Tools

* Image Usage & Resolution